{
    "clinical_study": {
        "@rank": "55460", 
        "arm_group": {
            "arm_group_label": "Alclometasone dipropionate cream", 
            "arm_group_type": "Experimental", 
            "description": "Alclometasone dipropionate cream 0.05% will be applied by the participants topically on the affected areas per label instructions for 14 days."
        }, 
        "brief_summary": {
            "textblock": "This is a multi-center, open-label study to evaluate whether participants follow the\n      duration of use instructions for short-term use of alclometasone dipropionate in a\n      population of participants with itchy skin conditions who would use OTC treatments for\n      relief. The study population will be composed of two different cohorts: chronic condition\n      sufferers (eczema or psoriasis) and participants who suffer from occasional itchy skin\n      experiences (such as poison ivy, oak, sumac, insect bites, or skin irritations due to\n      jewelry, cosmetics, detergents, or soaps) where an anti-itch medication would be used."
        }, 
        "brief_title": "Study to Evaluate Product Duration of Use Experience With Alclometasone Dipropionate Cream", 
        "completion_date": {
            "#text": "November 2006", 
            "@type": "Actual"
        }, 
        "condition": [
            "Eczema", 
            "Allergy Symptoms", 
            "Psoriasis", 
            "Itch"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Eczema", 
                "Psoriasis"
            ]
        }, 
        "detailed_description": {
            "textblock": "Approximately 313 participants who are currently suffering from an itchy skin condition\n      caused by eczema or psoriasis or any occasional itchy skin experiences will be enrolled into\n      the study to get 250 participants who complete the study (at least 100 to each of the\n      cohorts). After evaluation of the study criteria, the site staff will dispense product and a\n      diary card to the subject to use over the next 14 days. At the end of the 14 days, each\n      participant will come to the research site to return the remaining product and undergo the\n      study termination interview with the Concentrics nurse via telephone. The study will be\n      conducted in approximately 15 research sites located throughout the United States (US)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age: At least 12 years of age.\n\n          -  Condition: Currently experiencing itch associated with one of the following skin\n             conditions:\n\n               -  psoriasis or eczema,\n\n               -  minor skin conditions such as those caused by poison ivy, oak, or sumac, insect\n                  bites, or use of cosmetics, soaps, detergents, or jewelry.\n\n          -  Compliance: Subject or subject's parent or legal guardian understands and is willing,\n             able and likely to comply with all study procedures and restrictions.\n\n          -  Consent: Subject or subject's parent or legal guardian demonstrates ability to read\n             and understand English and is willing to participate as evidenced by voluntary\n             written informed consent and has received a signed and dated copy of the informed\n             consent form (and assent as appropriate).\n\n        Exclusion Criteria:\n\n          -  Pregnancy: Women who are known to be pregnant (as self-reported) or who are intending\n             to become pregnant over the duration of the study. Women of childbearing potential\n             will be allowed to participate in the study so long as they are practicing a reliable\n             method of contraception (e.g. hormonal birth control such as pill, patch, implant or\n             injection; intrauterine device, double barrier methods, tubal ligation, vasectomized\n             spouse or abstinence).\n\n          -  Corticosteroid Use: Subject has used a corticosteroid treatment within two weeks of\n             the screening visit at the start of the study.\n\n          -  Breast-feeding: Women who are breastfeeding.\n\n          -  Allergy/Intolerance: Known or suspected intolerance or hypersensitivity to\n             alclometasone cream (or closely related compounds), or any of their stated\n             ingredients.\n\n          -  Participation in another clinical study or receipt of an investigational drug within\n             30 days of the screening visit at the start of the study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "12 Years"
        }, 
        "enrollment": {
            "#text": "310", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 28, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02075632", 
            "org_study_id": "P2200440"
        }, 
        "intervention": {
            "arm_group_label": "Alclometasone dipropionate cream", 
            "description": "Alclometasone dipropionate cream 0.05% (15 g)", 
            "intervention_name": "Alclometasone dipropionate cream", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Alclometasone dipropionate", 
                "Methylprednisolone"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Alclometasone dipropionate", 
            "Eczema", 
            "Psoriasis", 
            "Itch"
        ], 
        "lastchanged_date": "February 27, 2014", 
        "number_of_arms": "1", 
        "official_title": "A Mult-Center, Open-Label Study to Evaluate Product Duration of Use Experience With Aclometasone Diproprionate Cream", 
        "overall_official": {
            "affiliation": "GlaxoSmithKline", 
            "last_name": "GSK Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "November 2006", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "A participant was evaluable for analysis of the rate of incorrect use if he or she used the study medication at least once and provided use information at least 8 days after the enrollment visit.Participants who used study medication for more than 7 consecutive days were asked why they did so.\n* Participants were allowed to select multiple reasons also if applicable", 
            "measure": "Number of participants with incorrect duration of use of the medication", 
            "safety_issue": "Yes", 
            "time_frame": "Day1-Day 14"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02075632"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "The number of days on which study medication was used, was be summarized for all subjects and by cohort in evaluable subjects.", 
            "measure": "Number of times per day participants used the product", 
            "safety_issue": "No", 
            "time_frame": "Day1-Day14"
        }, 
        "source": "GlaxoSmithKline", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "GlaxoSmithKline", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2006", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}